[96a5a0]: / output / allTrials / identified / NCT00258960_identified.json

Download this file

355 lines (355 with data), 14.1 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
{
"info": {
"nct_id": "NCT00258960",
"official_title": "Phase IV/II Trial With the Combination of Pegylated Liposomal Doxorubicin (Caelyx), Cyclophosphamide and Trastuzumab in Patients With Metastatic Breast Cancer With Overexpression of Human Epidermal Growth Factor Receptor 2 (HER2)/Neu",
"inclusion_criteria": "* Patients must sign an informed consent before of specific procedures of clinical trial.\n* Patients with histologically confirmed breast cancer and overexpression of Her2neu.\n* Age> 18 years.\n* Eastern Cooperative Oncology Group (ECOG) equal or < 2.\n* Patients have not been treated previously with chemotherapy for metastatic disease.\n* Patients must have at least one measurable lesion according to RECIST criteria.\n* Patients should have an adequate organ function to tolerate chemotherapy.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
"exclusion_criteria": "* Patients with hypersensitivity reactions to any of the medications of the clinical trial.\n* Patients who are pregnant or lactating are not eligible.\n* Hepatic disease.\n* Not controlled active infection\n* Symptomatic metastatic brain cancer\n* Previous adjuvant treatment with anthracyclines with a total accumulated dose > 300 mg/m2 (Doxorubicin) or > 600 mg/m2 (Epirubicin)",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Patients must sign an informed consent before of specific procedures of clinical trial.",
"criterions": [
{
"exact_snippets": "Patients must sign an informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "signed",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients with histologically confirmed breast cancer and overexpression of Her2neu.",
"criterions": [
{
"exact_snippets": "histologically confirmed breast cancer",
"criterion": "breast cancer",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": "histologically confirmed"
}
]
},
{
"exact_snippets": "overexpression of Her2neu",
"criterion": "Her2neu",
"requirements": [
{
"requirement_type": "expression level",
"expected_value": "overexpression"
}
]
}
]
},
{
"line": "* Age> 18 years.",
"criterions": [
{
"exact_snippets": "Age> 18 years",
"criterion": "age",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Eastern Cooperative Oncology Group (ECOG) equal or < 2.",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) equal or < 2",
"criterion": "Eastern Cooperative Oncology Group (ECOG)",
"requirements": [
{
"requirement_type": "score",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* Patients have not been treated previously with chemotherapy for metastatic disease.",
"criterions": [
{
"exact_snippets": "Patients have not been treated previously with chemotherapy for metastatic disease.",
"criterion": "previous chemotherapy treatment for metastatic disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Patients must have at least one measurable lesion according to RECIST criteria.",
"criterions": [
{
"exact_snippets": "at least one measurable lesion according to RECIST criteria",
"criterion": "measurable lesion",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "lesion"
}
},
{
"requirement_type": "measurement standard",
"expected_value": "RECIST criteria"
}
]
}
]
},
{
"line": "* Patients should have an adequate organ function to tolerate chemotherapy.",
"criterions": [
{
"exact_snippets": "adequate organ function",
"criterion": "organ function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "tolerate chemotherapy",
"criterion": "chemotherapy tolerance",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "female"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 75 Years",
"criterions": [
{
"exact_snippets": "maximum age of 75 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 75,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Patients with hypersensitivity reactions to any of the medications of the clinical trial.",
"criterions": [
{
"exact_snippets": "hypersensitivity reactions to any of the medications of the clinical trial",
"criterion": "hypersensitivity reactions",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Patients who are pregnant or lactating are not eligible.",
"criterions": [
{
"exact_snippets": "Patients who are pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "lactating",
"criterion": "lactation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Hepatic disease.",
"criterions": [
{
"exact_snippets": "Hepatic disease",
"criterion": "hepatic disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Not controlled active infection",
"criterions": [
{
"exact_snippets": "Not controlled active infection",
"criterion": "active infection",
"requirements": [
{
"requirement_type": "control status",
"expected_value": false
}
]
}
]
},
{
"line": "* Symptomatic metastatic brain cancer",
"criterions": [
{
"exact_snippets": "Symptomatic metastatic brain cancer",
"criterion": "metastatic brain cancer",
"requirements": [
{
"requirement_type": "symptomatic",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [
{
"line": "* Previous adjuvant treatment with anthracyclines with a total accumulated dose > 300 mg/m2 (Doxorubicin) or > 600 mg/m2 (Epirubicin)",
"criterions": [
{
"exact_snippets": "Previous adjuvant treatment with anthracyclines",
"criterion": "previous adjuvant treatment with anthracyclines",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "total accumulated dose > 300 mg/m2 (Doxorubicin)",
"criterion": "total accumulated dose of Doxorubicin",
"requirements": [
{
"requirement_type": "dose",
"expected_value": {
"operator": ">",
"value": 300,
"unit": "mg/m2"
}
}
]
},
{
"exact_snippets": "total accumulated dose > 600 mg/m2 (Epirubicin)",
"criterion": "total accumulated dose of Epirubicin",
"requirements": [
{
"requirement_type": "dose",
"expected_value": {
"operator": ">",
"value": 600,
"unit": "mg/m2"
}
}
]
}
]
}
],
"failed_miscellaneous": []
}